title: 28-day repeated oral toxicity study of a hypolipidemic agent, NK-104 in rats.
abstract: NK-104, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, was administered orally to Wistar rats at a dose of 2, 10, 50 or 100 mg/kg for 28 days consecutively, and the toxicity of NK-104 and its recovery with 2 weeks cessation of drug treatment were examined. As major clinical signs, loose stool, diarrhea, crouching and emaciation were observed in both sexes at 50 or 100 mg/kg, and all females at 100 mg/kg died or became moribund due to severe emaciation before the completion of treatment. The suppression of body weight gain or decrease in body weight was observed in the female dose group at 50 mg/kg and both sexes at 100 mg/kg. Decreased food intake was observed in both sexes at 100 mg/kg. Moreover, an increase in cholinesterase (Ch.E) in the male dose groups at 50 and 100 mg/kg and an increase in glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) in the female dose group at 50 mg/kg were observed in blood chemistry testing. Macroscopic examination showed thickening of the forestomach mucosa in the groups of 10 mg/kg or more. Microscopic examination revealed hyperkeratosis and hypertrophy of the spinous layer associated with both cell infiltration of the mucosal propria and submucosal edema. In addition, skeletal muscle lesions including atrophy, vacuolation and focal necrosis were observed in the female dose groups at 50 and 100 mg/kg. The above-mentioned microscopic changes were not observed on cessation of drug treatment. The non-toxic dose level of NK-104 in the 28-day repeated oral toxicity study using rats was determined to be 2 mg/kg.
authors.affiliation: Fuji Research Laboratories Pharmaceutical Division, Kowa Company Ltd., Shizuoka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Akiba
authors.forename: T
authors.initials: T
authors.lastname: Shibuta
authors.forename: Y
authors.initials: Y
authors.lastname: Amano
authors.forename: M
authors.initials: M
authors.lastname: Okubo
authors.forename: A
authors.initials: A
authors.lastname: Asanuma
authors.forename: T
authors.initials: T
authors.lastname: Koga
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
authors.forename: M
authors.initials: M
authors.lastname: Takimoto
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002802:Cholinesterases / Q000097:blood; D003967:Diarrhea / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D004614:Emaciation / Q000139:chemically induced; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000633:toxicity*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects; D019055:No-Observed-Adverse-Effect Level; D011804:Quinolines / Q000008:administration & dosage / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011804:Quinolines; D002802:Cholinesterases; C108475:pitavastatin